Ocular Therapeutix Reports Q4 2025 Results; Confirms Imminent AXPAXLI Wet AMD Phase 3 Data Release
OCUL sits 56% above its 52-week low of $5.785.
Summary
Ocular Therapeutix reported mixed Q4 and full-year 2025 financial results, including a revenue decline, but confirmed the imminent release of pivotal SOL-1 Phase 3 data for AXPAXLI in wet AMD in late February 2026.
Key Events · Product Development and Regulatory · OCUL
-
Q4 & Full-Year 2025 Financials
Reported a 22.4% decrease in Q4 2025 net revenue to $13.3 million and an 18.5% decrease for the full year to $52.0 million, alongside increased net losses and R&D expenses.
-
Strong Cash Position
Ended 2025 with $737.1 million in cash, providing an expected operational runway into 2028, supported by a $475 million equity offering in September 2025.
-
Imminent SOL-1 Phase 3 Data
Confirmed that topline 52-week results for the pivotal AXPAXLI (OTX-TKI) SOL-1 superiority trial in wet AMD are expected to be presented at the 49th Macula Society Annual Meeting (February 25-28, 2026).
-
Accelerated SOL-R Phase 3 Data
Completed randomization for the SOL-R non-inferiority trial in wet AMD, accelerating topline results anticipation to Q1 2027.
Analysis · OCUL · Life Sciences
This 8-K filing provides a critical update on Ocular Therapeutix's financial health and, more importantly, its lead clinical program, AXPAXLI. While the reported revenue decline and increased net loss for Q4 and full-year 2025 are negative, the company's strong cash balance, bolstered by a recent equity offering, provides a substantial runway into 2028. The most significant aspect of this filing is the confirmation of the imminent release of topline 52-week data from the pivotal SOL-1 Phase 3 trial for AXPAXLI in wet AMD, expected in late February 2026. This data represents a major binary event for the company and will be a primary driver of investor sentiment and stock performance. The company's decision to forgo a Q4 earnings call due to a quiet period underscores the market-moving importance of the upcoming clinical trial results. Additionally, the acceleration of SOL-R Phase 3 data to Q1 2027 and the ongoing HELIOS-3 trial for diabetic retinopathy highlight continued pipeline progress. Investors should closely monitor the SOL-1 data presentation for its potential impact on the company's future and the planned NDA submission.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCUL was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $5.79 to $16.44. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.